Blockchain

Catizen’s $CATI Token Lists on Multiple Exchanges

on

    More in Blockchain:

    Singapore, Singapore, September 20th, 2024, Chainwire

    Mantle’s flagship game, Catizen, officially launched its token, $CATI, on multiple exchanges today, including Binance, OKX, Bybit, Gate.io, and Bitget. As the most profitable mini-game on Telegram, Catizen seamlessly integrates Telegram with The Open Network / TON (L1) and Mantle Network (L2). $CATI, as the universal token of the Catizen ecosystem, is issued on both the TON and Mantle. It can be used in the mini-app center and open tasks, providing users with the opportunity to participate in the Launchpool “Stake to Earn,” further promoting the development of the entire gaming ecosystem.

    The $CATI token will exist in a parallel relationship on TON and Mantle, with a maximum supply of 1 billion tokens on each. However, the actual total supply will remain at 1 billion across the two blockchains through a locking mechanism. Currently, cross-chain transfers of $CATI can be done through Bybit exchange. The balance between the two chains is maintained through mutual locking contracts. For example, if Catizen airdrops 10 million $CATI to Mantle game users, 990 million $CATI of the 1 billion on Mantle Network will enter the locking contract, while 10 million $CATI of the 1 billion on TON will enter the locking contract to ensure that the total circulation on both chains remains capped at 1 billion.

    Since receiving Mantle EcoFund’s major investment in February 2023, Catizen, developed by Pluto Studio, has skyrocketed in popularity, becoming one of the most successful blockchain games globally, with over 36 million players. Catizen’s success can be reflected in the following impressive metrics:

    • Over $30 million in revenue generated within just 6 months
    • Over 7 million Daily Active Users (DAU)
    • 3 million on-chain users, with over 600,000 on the Mantle blockchain
    • Over 1 million paying users, with an Average Revenue per Paying User (ARPPU) of $27, totaling $27 million in revenue
    • More than 1 million MNT and 40 million $FISH tokens distributed as rewards exclusively to Mantle Catizen users
    • High-quality transactions: users bind wallets, sign contracts, and pay gas fees in MNT or TON for each transaction. More than half of the wallets hold at least $10 or more in assets

    By providing exclusive benefits through the Mantle and TON, Catizen has demonstrated its unparalleled ability to onboard users into Web3 on a massive scale, leading the next wave of Web3 gaming economies.

    For more information:

    Catizen on Mantle statistics: https://dune.com/hashed_official/catizen-mantle 

    $CATI airdrop details: https://x.com/CatizenAI/status/1833554571219898749

    About Mantle

    Mantle Ecosystem comprises an Ethereum layer 2 (L2) — Mantle Network, a decentralized autonomous organization (DAO) — Mantle Governance, one of the largest on-chain treasuries — Mantle Treasury, and an Ether (ETH) liquid staking protocol — Mantle LSP: all built on Ethereum. Mantle token ($MNT) is the unified product and governance token of the ecosystem. 

    Mantle’s first core product is Mantle Network, an Ethereum L2. Mantle Network strives to be compatible with the Ethereum Virtual Machine (EVM). Mantle Network’s modular architecture separates transaction execution, data availability, and transaction finality into modules — which can be individually upgraded and adopt the latest innovations. Mantle Network is the first L2 to partner with ETH restaking protocol EigenLayer for the data availability module. By adopting a rollup architecture, Mantle Network is secured by Ethereum. As the world’s first DAO-spawned L2, Mantle Network is pioneering a vision for the mass adoption of token-governed technologies. The current mainnet version, Mantle Network Mainnet v2 Tectonic (Mantle v2 Tectonic), went live on March 15, 2024.

    Mantle Network’s infrastructure is meticulously designed to handle the demands of the web3 gaming stack, enabling the creation of a connected and expansive gaming universe where assets have real value beyond a single game’s ecosystem. Closely intertwined with Mantle initiatives such as Hyperplay, Mantle Network’s ecosystem of expertise and resources facilitates a streamlined process for developers to build and deploy their gaming projects.

    To support the next-generation of innovators, builders, and developers, Mantle is growing its ecosystem via Mantle Grants Program and Mantle EcoFund, a catalyzed capital pool of $200M. Mantle’s Showcase Apps program lends additional support and publicity to ecosystem projects in categories such as real world assets (RWA). 

    For more information, readers can please visit:

    Website | X/Twitter | Devs X/Twitter | Discord | Telegram | YouTube | Blog | GitHub

    About Catizen

    Catizen is a revolutionary gaming bot on Telegram that seamlessly integrates the messaging app Telegram with multiple blockchains, including TON and Mantle Network. It redefines Web 3.0 experiences by enabling mobile payments with both crypto currencies and fiat currencies. By tapping into Telegram’s vast user base, Catizen aims to create a Web 3.0 traffic hub on an unprecedented scale.

    Additionally, Catizen is evolving into a Mini-app Center, integrating features from launchpool platforms, such as early access to new projects, token-based activities, transaction capabilities, along with short videos and e-commerce functionalities. This innovative approach will attract and engage users through gamification and strategic Play-to-Airdrop initiatives, transforming how users access and engage with the Web 3.0 ecosystem.

    For more information, readers can please visit: 

    X | Official Website | Telegram | Telegram Chat | Bot

    Contact

    Mantle’s Communications Team
    Mantle
    windrangerlabs@wachsman.com

    PostAd_coinrule_banner728x90

    Leave a Comment

    Your email address will not be published. Required fields are marked *

    *

    PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics

    2024-09-19T13:00:00Z

    Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes

    AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions.

    Prof. Mark Hoogendoorn, Co-CEO and Co-Founder PersonalAIze: "The strategic partnership between PersonalAIze and Cube has the potential to provide a transformative leap in healthcare diagnostics, uniting cutting-edge AI with trusted, high-performance capabilities and industry related in-depth expertise.”

    Frank van Asch, Founder and CTO of RenovaroCube,” Together, we are pioneering a future where healthcare outcomes are improved by training models for multiple decisions through the entire health journey, ensuring the right accuracy for therapeutic decisions in every disease stage.”

    The first phase of the collaboration focuses on establishing a strong foundation for the partnership, with PersonalAIze providing critical expertise in the integration of AI into healthcare. It will enhance existing collaborations with Academic and corporate partners and create new ones to build an eco-system to help develop and bring to the market a cutting-edge SaaS model and the next generation highly accurate diagnostics, starting with cancer.

    Prof Sandjai Buhlai, Co-CEO and Co-Founder PersonalAIze: “This collaboration signals a bold step forward in utilizing the full potential of AI potentially to help revolutionize early-stage medical interventions and diagnosis at the earliest stage of cancer before imaging has been able to detect the tumors.”

    Key contributions from PersonalAIze include:

    • Ethical AI: Ensuring the AI models are free from harmful biases and trained to support fairness and inclusivity in medical diagnostics.
    • Legal Guidance: Providing expert advice on legal responsibilities tied to AI outputs, including issues of AI accountability and potential liability.
    • Regulatory Compliance: Assisting in navigating existing and emerging regulations such as NEN, ISO, GDPR, and the AI Act, ensuring the platform adheres to all relevant healthcare regulations and clinical guidelines.
    • Medical and Diagnostic Input: Offering support in clinical validation in collaboration with medical scientists to ensure the AI is reliable and effective in real-world medical environments.
    • Explainable AI: Developing AI models that are transparent, fostering trust and confidence from both healthcare providers and patients.

    Key Resources and Support from PersonalAIze
    As part of the collaboration, PersonalAIze will contribute:

    • Expert Personnel: Including a Principal Investigator (PI) to lead clinical AI efforts, a project manager to coordinate the collaboration and a strategic advisor to oversee the scientific strategy and execution.
    • Research and Talent Capacity: Leveraging academic partnerships to ensure access to cutting-edge research and innovation and facilitating talent scouting to support the project’s development.
    • Academic Spin-Out Opportunities: Supporting the commercialization of academic research through potential spin-out ventures related to AI diagnostics.
    • Co-Development of AI Platform: Jointly developing a science-driven, evidence-based AI platform that meets rigorous clinical and regulatory standards.
    • Ongoing Research and Publications: Contributing to the body of research through support with peer-reviewed publications in collaboration with clinical experts that will help build trust within the medical community and among regulatory bodies.
    • Architecture and Strategy Guidance: Continuously advising on the platform’s architecture and strategic direction, ensuring it stays aligned with the latest industry trends and scientific advancements.
    • Trusted AI: Developing a trustworthy, explainable AI platform that inspires confidence among healthcare providers and patients through clear and transparent decision-making processes.

    About PersonalAIze
    PersonalAIze focuses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision-making systems as well as improvement of health care operations such as capacity planning.

    About Renovaro
    Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

    RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.

    Forward-Looking Statements
    Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    For media inquiries, please contact: karen@renovarocube.com

    Source: Renovaro Inc.


    GlobeNewsWire News

    Recent Comments